Efficacy and Side Effects of a Triple Drug Regimen for the Eradication of Helicobacter pylori

References

• McNulty C AM, Gearty Crump JC. Campylobacter pyloridis associated gastritis: investigator-blind, placebo-controlled trial of bismuth salicylate and erythromycin cthylsuccinate. Br Med J 1986; 293: 645–9
   PubMed Web of Science ®Google Scholar
• Rauws E AJ, Langcnberg W, Houthoft H J, Zanen H C, Tytgat G NJ. Campylobacter pyloridis-associated chronic active antral gastritis: a prospective study of its prevalence and the effects of antiulcer treatment. Gastroenterology 1988; 94: 33–40
   PubMedGoogle Scholar
• Morgan Kraft D., Bender W. M. Nitrofurans in the treatment of gastritis associated with Campylobacter pyloridis. Gastroenterology 1988; 95: 1178–84
   PubMedGoogle Scholar
• Glupczynski Y, Burette A, Labbe M, Dcprez C, De Reuck M, Deltcnrc M. Campylobacter pylori-associalcti gastritis: a double-blind placebo-controlled trial with amoxicillin. Am J Gastroenterol 1988; 83: 365–72
   PubMed Web of Science ®Google Scholar
• Valle J, Seppälä K, Sipponen P, Kosunen T. Disappearance of gastritis after eradication of Helicobacter pylori: a morphometric study. Scand J Gastroenterol 1991; 26: 1057–65
   PubMed Web of Science ®Google Scholar
• Coghlan J G, Gilligan D, Humphries H. Campylobacter pylori and the recurrence of duodenal ulcers–a 12 month follow-up study. Lancet 1987; 2: 1109–11
   PubMed Web of Science ®Google Scholar
• Lambert J R, Borremeo M, Korman M G, Hansky J, Eaves E R. Effect of colloidal bismuth (Denol) and healing relapse of duodenal ulcer–role of Campylobacter pyloridis [abstract]. Gastroenterology 1987; 92: 1489
   Web of Science ®Google Scholar
• Borody T J, Cole P, Noonan S. Long term Campylobacter pylori recurrence post eradication [abstract]. Gastroenterologv 1988; 94: 43
   Web of Science ®Google Scholar
• Smith A C, Price A B, Borriello P, Levi A J. A comparison of ranitidine and tripotassium dicitrato bismuth (TDB) in relapse rate of duodenal ulcer. The role of Campylobacter pylori [abstract]. Gastroenterology 1988; 94: 431
   Web of Science ®Google Scholar
• Marshall B J, Goodwin C S, Warren J R. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988; 2: 1437–42
   PubMed Web of Science ®Google Scholar
• Rauws E AJ, Tytgat G NJ. Cure of duodenal ulcer associated with eradication at Helicobacter pylori. Lancet 1990; 335: 1233–5
   PubMed Web of Science ®Google Scholar
• George L L, Borody T J, Andrews P. Cure of duodenal ulcer after eradication of Helicobacter pylori. Med J Austr 1990; 153: 145–9
   PubMed Web of Science ®Google Scholar
• Patchett S, O'Riordan Leen T.E, Keane C, O'Morain C. A prospective study of Helicobacter pylori eradication in duodenal ulcer. Gastroenterology 1990; 98: A104
   PubMed Web of Science ®Google Scholar
• Graham D Y, Lew G M, Klein P D. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric and duodenal ulcer. A randomised, controlled study. Ann Intern Med 1992; 116: 705–8
   PubMed Web of Science ®Google Scholar
• Mannes G A, Bayerdörffer E, Höchter W. Decreased relapse rate after antibacterial treatment of Helicobacter pylori-associated duodenal ulcers. Munich duodenal ulcer trial. Eur J Gastroenterol Hepatol 1993; 5: 145–53
   Web of Science ®Google Scholar
• Wormsley K G. Relapse of duodenal ulcer. Br Med J 1986; 293: 1501
   PubMedGoogle Scholar
• Boyd E JS, Wilson J A, Wormsley K G. Recurrent ulcer disease. Ranitidine: therapeutic advances, J J Misiewicz, J R Wood. Excerpta Medica, Amsterdam 1984; 14–42
   Google Scholar
• Chiba N, Rademaker J W, Rao B V, Hunt R H. Eradication of Helicobacter pylori–meta-analysis to determine optimal therapy. Gut 1991; 32: A1220–21
   Web of Science ®Google Scholar
• Tytgat G NJ, Axon A TR, Dixon M F. Helicobacter pylori: causal agent in peptic ulcer disease?. Working Party Report of the World Congress of Gastroenterology. Blackwell Scientific Publications, Melbourne 1990; 36–45
   Google Scholar
• Marshall B J, Hoffman S R, McCallum R W. Incidence of side-effects during bismuth sub-salicylate and antibiotic therapy for H. pylori (Hp). Gastroenterology 1991; 100: A117
   Google Scholar
• Graham D Y, Börsch G MA. The who's and when's of therapy for Helicobacter pylori. Am J Gastroenterol 1990; 85: 1552–5
   PubMed Web of Science ®Google Scholar
• Graham D Y, Lew G M, Malty H M. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992; 102: 493–6
   PubMed Web of Science ®Google Scholar
• Weil Bell J. G, Powell D. K. Helicobacter pylori infection treated with a tripotassium dicitrato bismuthate and metronidazole combination. Aliment Pharmacol Ther 1990; 4: 651–7
   PubMedGoogle Scholar
• Glupczynski Y, De Burette A., Koster E. Metronidazole resistance in Helicobacter pylori. Lancet 1990; 335: 976–7
   PubMed Web of Science ®Google Scholar
• Glupczynski Y, Burette A. Drug therapy for Helicobacter pylori infection: problems and pitfalls. Am J Gastroenterol 1990; 85: 1545–51
   PubMed Web of Science ®Google Scholar
• Hirschl A M, Hentschel E, Berger J, Nemec H, Rotter M L. Treatment of Helicobacter pylori infections with amoxycillin plus metronidazole: bacteriological, serological and histological results. Eur J Gastroenterol Hepatol 1991; 3: 3–7
   Web of Science ®Google Scholar
• Logan R PH, Gummet P A, Misiewicz J J, Karim O N, Walker M M, Baron J H. One week eradication regimen for Helicobacter pylori. Lancet 1991; 338: 1249–52
   PubMed Web of Science ®Google Scholar
• Rautelin H, Seppälä K, Renkonen O, Vainio V. U, Kosunen T U. Role of metronidazole resistance in therapy of Helicobacter pylori infections. Antimicrob Agents Chemother 1992; 36: 163–6
   PubMed Web of Science ®Google Scholar
• Van Zwet A, Thijs A. J, Oom C. JAJ, Hoogeveen J, Duringshoff B L. Failure to eradicate Helicobacter pylori in patients with metronidazole resistant strains. Eur J Gastroenterol Hepatol 1993; 5: 185–6
   Google Scholar
• Queiroz D MM, Mendes E N, Rocha G A. Indicator medium for isolation of Campylobacter pylori. J Clin Microbiol 1987; 25: 2378–9
   PubMed Web of Science ®Google Scholar
• Heatly R V. Review article: the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1992; 6: 291–303
   PubMedGoogle Scholar
• Van Zwet A A, Thijs J C, Kooistra-Smid A MD, Schirm J, Snijder J AM. Sensitivity of culture compared with that of polymerase chain reaction for detection of Helicobacter pylori from antral biopsy samples. J Clin Microbiol 1993; 31: 1918–20
   PubMedGoogle Scholar
• A multicenter collaborative study group. for in vitro susceptibility testing of H. pylori: metronidazole resistance in Helicobacter pylori: results of the second multicenter in vitro study [abstract]. Fourth Workshop of the European Helicobacter study group. Ital J Gastroenterol 1991; 23(Suppl 2)P292
   Google Scholar
• Burette A, Glupczynski Y, De Prez C. Evaluation of various multi-drug eradication regimens for Helicobacter pylori. Eur J Gastroenterol Hepatol 1992; 4: 817–23
   Web of Science ®Google Scholar
• Bell G D, Powell K, Burridge S M. Experience with ‘triple’ anti-Helicobacter pylori eradication therapy: side effects and importance of testing the pre-treatment bacterial isolate for metronidazole resistance. Aliment Pharmacol Ther 1992; 6: 427–35
   PubMed Web of Science ®Google Scholar
• Graham D. Panel discussion: short-term and long-term consequences of gastritis and duodenitis. Eur J Gastroenterol Hepatol, N J Tytgat, L Demling, A TR Axon, et al, 1992; 4: S53–64, Suppl 2
   Google Scholar
• Goodwin C S, Marshall B J, Blincow E D, Wilson D H, Black-Bourn S, Phillips M. Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies. J Clin Pathol 1988; 41: 207–10
   PubMed Web of Science ®Google Scholar